Abstract: The present invention relates to an unsaturated fatty acid-conjugated CP2c-targeting peptide-based agent. In the present invention, it was confirmed that by linking an unsaturated fatty acid to ACP52C, which is a CP2c-targeting peptide lead substance exhibiting an effect as a general-purpose anticancer agent, in vivo stability was improved without affecting the anticancer effect. Further, cancer cell-specific anticancer efficacy was confirmed in various cancer cells and normal cells.

Abstract: The presented invention relates to a CP2c-targeting peptide-based anticancer agent. A CP2c-targeting peptide according to the presented invention binds to transcription factor CP2c to inhibit the formation of transcription factor CP2c complexes (CP2c homotetramer and CP2c/CP2b/PIAS1 heterohexamer), thereby inducing cancer cell-specific cell death. A fatty acid is bound to the peptide to ensure stability enabling long-term sustenance in vivo.

Abstract: The present invention relates to a peptide having anticancer activity, and a pharmaceutical composition, health functional food composition and functional cosmetic composition for preventing and treating cancer including the same as an active ingredient, and more particularly, to a peptide set forth in SEQ ID NO: 1, wherein the peptide binds to a transcription factor CP2c and has prophylactic and therapeutic activities against cancer, and a pharmaceutical composition, a health functional food composition and a functional cosmetic composition for preventing and treating cancer including the same as an active ingredient. <SEQ ID NO: 1> Tyr-Pro-Gln-Arg.

Abstract: The present invention relates to a composition including an inhibitor against the function of an Mi-2/NuRD chromatin remodeling complex for inhibiting metastasis and preventing and treating cancer diseases, and more particularly, the composition may inhibit the MBD2-p66? (GATAD2A) interaction by means of the Mi-2/NuRD CRC function inhibitor, and thus is expected to be effectively used as a composition capable of inhibiting metastasis and preventing and treating cancer diseases.

Abstract: A peptide binding to transcription factor CP2c, having an activity of preventing and treating cancer and represented by SEQ ID NO: 1: Asn-Tyr-Pro-Gln-Arg-Pro, and a pharmaceutical composition and a dietary supplement composition for preventing and treating cancer, both of which contain the same as an active ingredient are disclosed. When cancer cells are treated with the peptide and the pharmaceutical composition containing the same, the peptide can specifically bind to CP2c by passing, with very high stability, through the cell membrane and can inhibit the DNA binding ability of CP2c, thereby disturbing CP2c-mediated cancer cell-specific transcriptional activity through the inhibition of CP2c activity. Thus, the peptide and pharmaceutical composition containing the same can be effectively used for specifically treating only cancer cells and can be utilized for cancer prevention and as a dietary supplement additive therefor.

Abstract: A method of discovering a drug candidate, comprising: a step in which a computer device uses bioinformatics to determine a disorder-to-order transition region of a target protein; a step in which the computer device performs molecular docking on the disorder-to-order transition region in conjunction with a library of specific compounds to select first candidate compounds capable of binding to the disorder-to-order transition region from among the compound library; and a step in which the computer device performs a molecular dynamics simulation for the first candidate compounds and the disorder-to-order transition region to select a second candidate compound from among the first candidate compounds.

Abstract: The present invention relates to a peptide having anticancer activity, and a pharmaceutical composition, health functional food composition and functional cosmetic composition for preventing and treating cancer including the same as an active ingredient, and more particularly, to a peptide set forth in SEQ ID NO: 1, wherein the peptide binds to a transcription factor CP2c and has prophylactic and therapeutic activities against cancer, and a pharmaceutical composition, a health functional food composition and a functional cosmetic composition for preventing and treating cancer including the same as an active ingredient.

Abstract: The present invention relates to a composition including an inhibitor against the function of an Mi-2/NuRD chromatin remodeling complex for inhibiting metastasis and preventing and treating cancer diseases, and more particularly, the composition may inhibit the MBD2-p66? (GATAD2A) interaction by means of the Mi-2/NuRD CRC function inhibitor, and thus is expected to be effectively used as a composition capable of inhibiting metastasis and preventing and treating cancer diseases.

Abstract: The present invention relates to a peptide having an anticancer activity, and a pharmaceutical composition and a dietary supplement composition for preventing and treating cancer, both of which contain the same as an active ingredient and, more specifically, to a peptide binding to transcription factor CP2c, having an activity of preventing and treating cancer and represented by SEQ ID NO: 1, and a pharmaceutical composition and a dietary supplement composition for preventing and treating cancer, both of which contain the same as an active ingredient.

Abstract: Provided is a regenerative cell extraction system. The regenerative cell extraction system includes: a regenerative cell separation unit which separates fat tissue; and a regenerative cell extraction unit. The regenerative cell separation unit includes: a sub container which is rotated by a torque applied from an external source and includes a space in which fat tissue is housed; a hollow main pipe which is inserted into the sub container; and a pump which is connected to the main pipe. In addition, the regenerative cell extraction unit receives a regenerative cell-containing substance, which is obtained after the fat tissue is centrifuged by the regenerative cell separation unit, from the regenerative cell separation unit, and extracts regenerative cells from the substance by centrifuging the substance.

Abstract: Provided is a regenerative cell extraction system. The regenerative cell extraction system includes: a regenerative cell separation unit which separates fat tissue; and a regenerative cell extraction unit. The regenerative cell separation unit includes: a sub container which is rotated by a torque applied from an external source and includes a space in which fat tissue is housed; a hollow main pipe which is inserted into the sub container; and a pump which is connected to the main pipe. In addition, the regenerative cell extraction unit receives a regenerative cell-containing substance, which is obtained after the fat tissue is centrifuged by the regenerative cell separation unit, from the regenerative cell separation unit, and extracts regenerative cells from the substance by centrifuging the substance.

Abstract: The present invention relates to a composition for transplantation in a physiologically compatible buffer solution comprising, (a) a transplant-cell selected among an adipose stem cell, an adipocyte, adipose tissues (fat tissue) and a mixture thereof; and (b) a semi-solid substance derived from a living body or a biodegradable substance selected among a hyaluronic acid, collagen, elastin, thrombin, chondroitin sulfate, albumin and a mixture thereof.

Abstract: Disclosed herein are an expression vector of mud loach growth hormone gene and a fast-growing transgenic mud loach transformed with the expression vector. Also disclosed herein is an expression vector containing &bgr;-actin gene regulation site of mud loach which is constructed for expression of useful genes in fishes. The transgenic mud loaches transformed with the expression vector of mud loach growth hormone gene show growth rate of 25 times higher than that of normal mud loaches.